Description
BSE announces the revocation of suspension in trading of equity shares of Vivimed Labs Limited (Scrip Code: 532660).
Summary
BSE has revoked the suspension on trading of equity shares of Vivimed Labs Limited (Scrip Code: 532660). Trading in the company’s equity shares can now resume on the exchange platform.
Key Points
- Trading suspension in equity shares of Vivimed Labs Ltd has been revoked
- Scrip Code: 532660
- Trading can resume immediately
- The revocation applies to equity shares on BSE platform
Regulatory Changes
The suspension that was previously imposed on trading of Vivimed Labs equity shares has been lifted, allowing normal trading activities to resume.
Compliance Requirements
- Trading members can resume accepting orders for Vivimed Labs equity shares
- Normal trading rules and regulations apply
- Standard market timings and procedures are applicable
Important Dates
- Effective Date: December 10, 2025
- Trading resumes from the effective date
Impact Assessment
Market Impact: High - The revocation of suspension restores liquidity and allows shareholders to trade their holdings. This is a positive development for existing shareholders who were unable to exit or enter positions during the suspension period.
Investor Impact: Shareholders of Vivimed Labs can now buy or sell their equity shares through the BSE platform. The resumption of trading provides price discovery mechanism and market access that was previously unavailable during the suspension period.
Operational Impact: Trading members and brokers can resume normal operations for this scrip, including accepting client orders, executing trades, and providing market-making services.
Impact Justification
Revocation of trading suspension allows investors to resume trading in the stock, which has high impact on liquidity and market access for shareholders of Vivimed Labs